Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

Introduction The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for ti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2020-07, Vol.37 (7), p.3404-3416
Hauptverfasser:	Huang, Shang-Yi, Yoon, Sung-Soo, Shimizu, Kazuyuki, Chng, Wee Joo, Chang, Cheng-Shyong, Wong, Raymond Siu-Ming, Gao, Seasea, Wang, Yang, Gordon, Steve W., Glennane, Anthony, Min, Chang-Ki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Asian Continental Ancestry Group - statistics & numerical data Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - etiology Brief Report Cardiology Denosumab - adverse effects Denosumab - therapeutic use Double-Blind Method Endocrinology Female Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Multiple Myeloma - complications Oncology Pharmacology/Toxicology Rheumatology Treatment Outcome Zoledronic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!